News UK's Mission divests kidney drug to Dimerix for $292m Mission Therapeutics has struck a deal to out-license a drug for acute kidney injury to Australia's Dimerix, sharpening its focus on CNS diseases.
Views & Analysis Will the UK ever produce a world-class biotech company? Kymab, F-star and Mission Therapeutics among crop of new UK biotechs.
News Mission Therapeutics raises £60m to advance novel ‘DUB’ drug... UK biotech company Mission Therapeutics has raised £60 million to invest into its drug discovery and development programme.
News ESC26: Isomab safety evidence on blood vessel growth for CAD Isomab has presented landmark safety data at ESC, clearing the path for next-generation therapies to promote blood vessel growth in CAD.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.